CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,203 enrolled
Drug / intervention
Levothyroxine +1 moredrug
Likely dose
Levothyroxine 100mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00388297
NCT00388297Phase 3Completed

A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy

The George Washington University Biostatistics Center·interventional·Posted Oct 16, 2006·Updated Feb 21, 2019

In Brief

A Phase 3 clinical trial evaluating Levothyroxine and Placebo for Levothyroxine for Subclinical Hypothyroidism and 2 related conditions. Completed, enrolled 1,203 participants across 14 sites.

Detailed Summary

The purpose of this study is to determine whether treating women, who are diagnosed with a mild imbalance of thyroid hormones during pregnancy, with thyroid hormone replacement affects their children's intellectual development at 5 years of age.

Study Details

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2006
Enrollment StartOct 1, 2006
Primary CompletionAug 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 19.7 years ago

Interventions

Levothyroxinedrug

Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.

Placebo for Levothyroxinedrug